Upadacitinib is marketed under which brand name?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $9.99Unlock all

Enhance your dermatological knowledge with the Dermatology Week 1 Exam. Engage with multiple choice questions that provide insights and detailed explanations to gear you up for testing success. Prepare effectively for your exam!

Multiple Choice

Upadacitinib is marketed under which brand name?

Explanation:
Upadacitinib is a targeted therapy in the JAK inhibitor class, and its brand name is Rinvoq. The other names correspond to different drugs: Olumiant is baricitinib (a JAK1/2 inhibitor), Xeljanz is tofacitinib (a pan-JAK inhibitor), and Remicade is infliximab (a TNF-alpha monoclonal antibody). Brand names help distinguish medications within similar drug classes, so Rinvoq is the commercially used name for upadacitinib in most markets.

Upadacitinib is a targeted therapy in the JAK inhibitor class, and its brand name is Rinvoq. The other names correspond to different drugs: Olumiant is baricitinib (a JAK1/2 inhibitor), Xeljanz is tofacitinib (a pan-JAK inhibitor), and Remicade is infliximab (a TNF-alpha monoclonal antibody). Brand names help distinguish medications within similar drug classes, so Rinvoq is the commercially used name for upadacitinib in most markets.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy